50. 皮膚筋炎／多発性筋炎 Dermatomyositis Clinical trials / Disease details
臨床試験数 : 194 / 薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000036709 | 2020-10-01 | 2020-08-24 | Study on early warning of rapid progressive interstitial lung disease in dermatomyositis | Study on early warning of rapid progressive interstitial lung disease in dermatomyositis | Dermatomyositis | Group 1:Glucocorticoid + cyclophosphamide + cyclosporin;Group 2:Glucocorticoid + cyclophosphamide + Tofacitinib; | Zhongshan Hospital of Fudan University | NULL | Pending | 18 | 60 | Both | Group 1:15;Group 2:15; | N/A | China |
| 2 | NCT04613219 (ClinicalTrials.gov) | October 1, 2020 | 15/9/2020 | Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease | Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease | Clinically Amyopathic Dermatomyisitis(CAMD) | Drug: Tofacitinib 5 MG [Xeljanz] | Jing Liang | NULL | Recruiting | 18 Years | 80 Years | All | 80 | China | |
| 3 | ChiCTR1800016629 | 2017-07-01 | 2018-06-14 | An observation of tofacitinib in patients of MDA5+ clinically amyopathic dermatomyositis with interstitial lung disease | An observation of tofacitinib in patients of MDA5+ clinically amyopathic dermatomyositis with interstitial lung disease | dermatomyositis | study group:tofacitinib;control group:glucocorticoids+immunosuppressant; | Ren Ji Hospital South Campus, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | 18 | 80 | Both | study group:15;control group:35; | China | |
| 4 | NCT03002649 (ClinicalTrials.gov) | January 2017 | 20/12/2016 | Study of Tofacitinib in Refractory Dermatomyositis | Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients | Dermatomyositis | Drug: Tofacitinib | Johns Hopkins University | Pfizer | Completed | 18 Years | N/A | All | 10 | Phase 1 | United States |